Acute cardiac care & resuscitationTrial design
Lower noradrenaline-mediated mean arterial pressure target in patients with acute myocardial infarction-related cardiogenic shock: rationale and design of the NORshock study
- international, open-label, multicentre, randomised superiority trial
- 1:1 allocation
Study context
- Population
- Patients with acute myocardial infarction-related cardiogenic shock (AMI-CS)patients to be allocated (planned)
- Participants
- 776 patients
- Planned comparison
- a lower noradrenaline-mediated mean arterial pressure (MAP)-target regimen (MAP of 55 mmHg) compared with a standard noradrenaline-mediated MAP-target regimen (MAP of at least 65 mmHg)
No results yet. This paper sets out the design of a trial; its results are to come.
Further findings
Study design (no results reported) · within 30 days
- Hypothesis: permissive hypotension strategy superior to standard care for combined endpoint of all-cause death and renal replacement therapy
- rationale and design paper
Original publication
Lower noradrenaline-mediated mean arterial pressure target in patients with acute myocardial infarction-related cardiogenic shock: rationale and design of the NORshock study. EuroIntervention. Published 7 September 2026. doi:10.4244/eij-d-26-00112
Summarised from the published abstract; every number is checked against it